J&J's Palmaz-Schatz stent
This article was originally published in The Gray Sheet
Six-month follow-up of a randomized trial comparing the Johnson & Johnson Heparin coated stent with balloon angioplasty in patients with acute myocardial infarction shows a 12.4% risk of death, repeat MI, disabling cerebrovascular accident and ischemia-driven target vessel revascularization in the stent arm compared to 20.1% in the angioplasty arm (p<0.01), the study's primary endpoint. Results from the 62-center, 900 patient trial were presented at an AHA press conference Nov. 9 by Cindy Grines, MD, William Beaumont Hospital, Royal Oak, Michigan. The results also show reduced restenosis in the stent arm (20.3% vs. 32.5%; p<0.001) and reduced angina (11.1% vs. 16.9%; p<0.02). Six-month reocclusion rates were also favorable compared to PTCA (10-13%) and thromobolytic therapy (30%), Grines noted. "In the era of stenting it looks like we've reduced that down to 4%, that's a major improvement and could potentially reduce rates of reinfarction" and improve LV function, Grines said
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.